Geron Total Current Liabilities from 2010 to 2025

GERN Stock  USD 1.65  0.05  2.94%   
Geron Total Current Liabilities yearly trend continues to be very stable with very little volatility. Total Current Liabilities is likely to grow to about 92.7 M this year. Total Current Liabilities is the total amount of liabilities that Geron is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. View All Fundamentals
 
Total Current Liabilities  
First Reported
1996-03-31
Previous Quarter
137.9 M
Current Value
88.3 M
Quarterly Volatility
26.2 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Geron financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Geron's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 M, Interest Expense of 19.4 M or Selling General Administrative of 153 M, as well as many indicators such as Price To Sales Ratio of 28.22, Dividend Yield of 0.0 or PTB Ratio of 8.57. Geron financial statements analysis is a perfect complement when working with Geron Valuation or Volatility modules.
  
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.

Latest Geron's Total Current Liabilities Growth Pattern

Below is the plot of the Total Current Liabilities of Geron over the last few years. Total Current Liabilities is an item on Geron balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Geron are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Geron's Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Geron's overall financial position and show how it may be relating to other accounts over time.
Total Current Liabilities10 Years Trend
Slightly volatile
   Total Current Liabilities   
       Timeline  

Geron Total Current Liabilities Regression Statistics

Arithmetic Mean36,221,619
Geometric Mean21,063,219
Coefficient Of Variation98.74
Mean Deviation29,470,648
Median28,162,000
Standard Deviation35,765,681
Sample Variance1279.2T
Range104.5M
R-Value0.82
Mean Square Error455.3T
R-Squared0.67
Significance0.0001
Slope6,138,821
Total Sum of Squares19187.8T

Geron Total Current Liabilities History

202592.7 M
202488.3 M
2023108.1 M
202276.7 M
202145.5 M
202030.9 M
201928.2 M

About Geron Financial Statements

Geron investors utilize fundamental indicators, such as Total Current Liabilities, to predict how Geron Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Total Current Liabilities88.3 M92.7 M
When determining whether Geron offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Geron's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Geron Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Geron Stock:
Check out the analysis of Geron Correlation against competitors.
To learn how to invest in Geron Stock, please use our How to Invest in Geron guide.
You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Geron. If investors know Geron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Geron listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.27)
Revenue Per Share
0.119
Quarterly Revenue Growth
2.1 K
Return On Assets
(0.22)
Return On Equity
(0.66)
The market value of Geron is measured differently than its book value, which is the value of Geron that is recorded on the company's balance sheet. Investors also form their own opinion of Geron's value that differs from its market value or its book value, called intrinsic value, which is Geron's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Geron's market value can be influenced by many factors that don't directly affect Geron's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Geron's value and its price as these two are different measures arrived at by different means. Investors typically determine if Geron is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Geron's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.